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Abstract
Context
Studies concerning the association between circulating resistin and mortality risk have re-
ported, so far, conflicting results.
Objective
To investigate the association between resistin and both all-cause and cardiovascular (CV)
mortality risk by 1) analyzing data from the Gargano Heart Study (GHS) prospective design
(n=359 patients; 81 and 58 all-cause and CV deaths, respectively); 2) performing meta-
analyses of all published studies addressing the above mentioned associations.
Data Source and Study Selection
MEDLINE andWeb of Science search of studies reporting hazard ratios (HR) of circulating
resistin for all-cause or CV mortality.
Data Extraction
Performed independently by two investigators, using a standardized data extraction sheet.
Data Synthesis
In GHS, adjusted HRs per one standard deviation (SD) increment in resistin concentration
were 1.28 (95% CI: 1.07-1.54) and 1.32 (95% CI: 1.06-1.64) for all-cause and CV mortality,
respectively. The meta-analyses included 7 studies (n=4016; 961 events) for all-cause
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mortality and 6 studies (n=4,187: 412 events) for CV mortality. Pooled HRs per one SD in-
crement in resistin levels were 1.21 (95% CI: 1.03-1.42, Q-test p for heterogeneity<0.001)
and 1.05 (95% CI: 1.01-1.10, Q-test p for heterogeneity=0.199) for all-cause and CV mortal-
ity, respectively. At meta-regression analyses, study mean age explained 9.9% of all-cause
mortality studies heterogeneity. After adjusting for age, HR for all-cause mortality was 1.24
(95% CI: 1.06-1.45).
Conclusions
Our results provide evidence for an association between circulating resistin and mortality
risk among high-risk patients as are those with diabetes and coronary artery disease.
Introduction
Several studies indicate that resistin, a 12.5 kDa cysteine-rich pro-inflammatory adipokine, is a
major promoter of atherosclerosis and related cardiovascular (CV) disease [1–7], including
heart failure [8].
Since CV disease is the first cause of mortality worldwide, resistin becomes a natural candi-
date to investigate as a possible mortality risk factor. In fact, conflicting results have been re-
ported on this subject [9–16].
To deeper understand the role of resistin on mortality rate, we firstly added new evidences
by trying to replicate our previous finding [14] in a second, independent sample of diabetic
patients followed over time for both all-cause and CV mortality and then performed a meta-
analysis of all published prospective studies on the association between circulating resistin and
mortality risk of either all-cause or CV origin.
Materials and Methods
Study Population
GHS-prospective design. This study comprises 368 patients with type 2 diabetes mellitus
(T2DM) (ADA 2003 criteria) and coronary artery disease (CAD) who were consecutively re-
cruited at the Endocrine Unit of IRCCS “Casa Sollievo della Sofferenza” in San Giovanni
Rotondo (Gargano, Center East Coast of Italy) from 2001 to 2008, as recently described [14,
17]. All patients had either a stenosis>50% in at least one coronary major vessel at coronary
angiography or a previous myocardial infarction (MI). Follow-up information on outcomes
was collected yearly from 2002 to 2011. The only exclusion criterion was the presence of poor
life expectancy for non diabetes-related diseases. The end-point was CV mortality and all-
cause mortality. Confirmation of the event was obtained from death certificates (i.e. according
to the international classification of diseases’ codes: 428.1- ninth edition—and I21.0-I21.9,
I25.9, I46.9-I50.9, I63.0, I63.9, I70.2—tenth edition).
Clinical data were obtained from a standardized interview and examination. Smoking habits
and history of hypertension, dyslipidemia and MI as well as glucose-lowering treatment were
also recorded at time of examination. Data regarding medications were confirmed by review of
medical records.
Serum resistin was measured in 359 (98%) participants by a commercial ELISA (Bio Ven-
dor, Brno Czech Republic) at the Research Unit of Diabetes and Endocrine Diseases in San
Giovanni Rotondo, as previously described [18].
Circulating Resistin Levels and Mortality Risk
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Ethics
The study was approved by the Institutional Ethic Committee IRCCS “Casa Sollievo della Sof-
ferenza”, San Giovanni Rotondo. All participants gave written consent.
Meta-Analysis of Prospective Studies
Search strategy and selection criteria. The present meta-analysis follows the Preferred
Reporting Items for Systematic Review and Meta-analyses (PRISMA) statements (S1 PRISMA
Checklist). Two investigators (S.S. and C.M.) independently searched MEDLINE andWeb of
Science for prospective studies with resistin as exposure and CV or all-cause mortality as out-
come, published until October 2014. Search terms used were (Resistin[Mesh] or RETN) and
(Mortality [Mesh] or death).
Reference lists of retrieved articles (online S1 Supporting Information) were hand-searched
for additional studies. Data gathered included: first author, publication year, location, study de-
sign, race/ethnicity, number of participants, number of events, proportion of males, duration
of follow-up, age, mean resistin levels and body mass index, events ascertainment and variables
controlled for. Each article identified by this search process was considered if it was a cohort
study published as original (abstracts, letters, reviews, and meta-analyses had been excluded)
and reported the adjusted hazard ratios (HR) or the natural logarithm of the HR (logHR) esti-
mates, along with their 95% confidence interval (95%CI) or standard error (SE) or p-value, for
each study-specific non-reference exposure level. When unavailable, the reported unadjusted
HRs were considered. Moreover, studies where HRs were expressed in terms of unitary incre-
ment of their resistin standard deviation (SD) were also considered.
Data preparation. Preparation of the data of the original studies for the meta-analysis fol-
lowed two stages. First, since different studies used different units of measure to express serum
resistin concentration doses, all the measures were converted into ng/ml as the
standard measure.
Second, as the levels of serum resistin concentration were often reported as the minimum-
maximum range for each tertile or quartile of the study-specific resistin distribution, the repre-
sentative dose value was assigned for each dose group by fitting a gamma distribution to the
serum resistin distribution over the range’s class. To estimate gamma parameters, study-
specific resistin mean and SD were used as suggested in Hartemink et al. [19]. When resistin
mean and SD were unavailable for a specific-study, median and interquartile range were used
instead, respectively. For the open-ended risk classes (e.g.,<2.7 or> 4.9), the representative
value was assigned following the algorithms suggested by Il’yasova et al. [20].
Statistics
Patients’ baseline characteristics were reported as mean ± SD and percentages for continuous
and categorical variables, respectively.
The time variable was defined as the time between the baseline examination and date of the
event, or, for subjects who did not experience the event, the date of the last available clinical fol-
low-up. Incidence rates for all-cause and CVmortality were expressed as the number of events
per total number of person-years (py). Risks were reported as HRs along with 95% CI.
Dose-response meta-analysis followed a two-step process and was performed for all-cause
and CV mortalities outcomes, separately.
Step 1: We considered those studies in which HRs were reported with respect to a study-
specific categorical reference dose of serum resistin concentrations (i.e. tertiles or quartiles) [9,
11–13]: study-specific slopes of logHR across exposure categories were estimated with weight-
ed log-linear models (WLM), using study-specific rescaled doses (with respect to the reference
Circulating Resistin Levels and Mortality Risk
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representative dose) as covariate and variances of logHRs (derived from SE or 95%CI or
p-values reported within each study) as weights. No intercept term was included in the model
since, by definition, when the rescaled dose is zero the linear function would start from
logHR = 0. Moreover, to account for between logHRs correlations within each study, plausible
pairwise covariance values were derived on the basis of known logHRs variances and possible
correlations values: 0, 0.2, 0.3, 0.5, 0.8, 1. Covariance values for which the model achieved the
minimum Akaike’s Information Criterion (AIC) were chosen.
Step 2: We considered those studies in which HRs were reported with respect to one incre-
ment of resistin SD (scaled unit of measure) [10, 14–16] and the current study: study-specific
slopes (logHRs) were estimated.
Step 3: Given that resistin measurement was carried out in different specimens (i.e. serum
or plasma), by different laboratories using different assays, we firstly converted the scaled mea-
sures with respect to one increment of study-specific SD, and then all study-specific slopes ob-
tained from Step 1 and Step 2 were combined and their summary statistics were estimated.
Statistical heterogeneity among studies was assessed using the Cochran Q-test and heterogene-
ity hold for p-values less than 0.10 [21]. Study-specific estimates were pooled using either the
fixed-effects model or, in presence of heterogeneity (i.e. Q-test statistically significant), the ran-
dom effects model [22]. Furthermore, to explain residual heterogeneity, meta-regression analy-
ses were performed using those study-level covariates which were available from all studies,
including age, sex, smoking habits, follow-up time, BMI, presence of diabetes, hypertension
and specimen of resistin measurement.
To evaluate consistency and stability of HRs estimates found from meta-analysis and meta-
regression, sensitivity analyses were carried out, by re-running all analyses after excluding one
study at one time.
Due to the small number of studies (fewer than ten) and the presence of substantial
between-study heterogeneity, following Sterne et al. [23] and Ioannidis et al. [24] recommenda-
tions, we did not perform tests for publication bias.
Forest plots were shown, where a square was plotted for each study whose center projection
on the underlying scale corresponded to the study-specific HR. The area of the square was pro-
portional to the inverse of the variance of the logHR and thus gives a measure of the amount of
statistical information available from that particular estimate. A diamond was used to plot the
summary HRs, the center of which represents the HR; the extremes of the summary HRs show
the 95% CI.
Bubble plot of study-specific logHRs is shown against the chosen study-level covariate
which explained the most proportion of heterogeneity. The size of each bubble was inversely
proportional to the standard error of specific logHR.
Two-sided p-values<0.05 were considered for statistical significance. Statistical analysis
were performed using SAS Software, Release 9.3 (SAS Institute, Cary, NC, USA) and R 2.15
(package: metafor).
Results
The GHS-prospective design
Clinical features of study participants are summarized in Table 1.
During follow-up (5.4 ±2.5 years for a total of 1,934 patient-years, py), 81 all-cause and 58
CV deaths occurred, corresponding to an annual incidence rate of 4.2 and 3.0 events per 100
person-years, respectively.
Circulating Resistin Levels and Mortality Risk
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Each SD (i.e. 6.6 ng/ml) increment of serum resistin was associated with an increased risk of
both all-cause and CV mortality (HR = 1.33, 95%CI: 1.17–1.52, p = 2x10-5 and HR = 1.34, 95%
CI: 1.14–1.57, p = 3x10-4, respectively; Table 2).
These associations were independent of clinical features including age, sex, smoking habits,
BMI, HbA1c, hsCRP, anti-diabetic, anti-hypertensive and anti-dyslipidemic treatments
(Table 2). Similar results were obtained after adding into the model also LDL and non HDL
(p = 0.014 and p = 0.018, respectively) cholesterol or when hsCRP was replaced by fibrinogen
into the model (p = 0.03 and p = 0.05, respectively).
Meta-Analysis of Prospective Studies
Eighty-seven hits fromMEDLINE andWeb of Science were retrieved (S1 Supporting Informa-
tion). After the exclusion of all articles which did not meet the inclusion criteria (Fig. 1 and
S1 Supporting Information), 6 independent studies on all-cause mortality [9, 11–14, 16] and 5
independent studies on CV mortality [10–12, 15, 16] were eligible for inclusion.
One hundred and three participants from our previous study on all-cause mortality, over-
lapped with those of the current study [14]. For this reason we have included, in the meta-analysis
for all-cause mortality, HR already reported inMenzaghi et al. [14] after the exclusion of the 103
overlapping patients. In all, with the inclusion of the present GHS, data from a total of 4,016 (961
incident cases) and 4,187 (412 incident cases) participants were meta-analyzed for either all-cause
or CVmortality respectively. Main features of all these studies are shown in Tables 3 and 4.
All studies were conducted in high risk patients with previous CAD [11, 13], MI [12], ische-
mic stroke [9, 10], T2DM [14, 15] or end stage renal disease [16] (Table 3). With the exception
Table 1. Clinical characteristics of patients from GHS-prospective design (n = 359).
Sex (% males) 67.4
Age (yrs) 64.5±8.1
Smokers (%) 45
Diabetes duration (yrs) 13.8±9.2
BMI (kg/m2) 30.2±4.8
HbA1C (%) 8.6±1.9
Total cholesterol (mg/dL) 175.8±45.7
HDL-cholesterol (mg/dL) 43.6±14.6
non-HDL-cholesterol (mg/dL) 131.3±43.5
LDL-cholesterol (mg/dL) 100.9±38.6
Triglycerides (mg/dL) 152.6±91.8
Glucose-lowering therapy
Diet only (%) 7
Oral agents (%) 35
Insulin ± oral agents (%) 58
Antihypertensive therapy (%) 85
Antidyslipidemic therapy (%)
hsCRP (mg/L)
65
6.1±12.7
Resistin (ng/ml) 10.7±6.6
Continuous variables were reported as mean± standard deviation whereas categorical variables
as percentages.
GHS: Gargano Heart Study; BMI: body mass index; HbA1c: glycated haemoglobin; HDL: high density
lipoprotein; LDL: low density lipoprotein; hsCRP: high sensitivity C-reactive protein.
doi:10.1371/journal.pone.0120419.t001
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of Lee et al. [12] and Zhang et al. [13], studies were carried out in Europeans (Table 3), with a
very similar study mean age, but a quite different study mean BMI (Table 4).
All-cause mortality (n = 7 studies). The number of subjects from each study ranged from
211 to 1162 with mean follow-up ranging from 1.0 to 7.8 years (Table 3).
Four studies [9, 11, 12, 14] reported a significant association as we have shown in our cur-
rent study. One displayed a directionally consistent but statistically insignificant association
[13], and the last one showed no association at all [16].
Fig. 2, panel A, shows the random effects meta-analysis for all-cause mortality whose pooled
HR per one increment in SD of resistin concentration was 1.21 (95%CI:1.03–1.42, p = 0.020).
Table 2. Risk of all-cause and cardiovascular mortality per one standard deviation (i.e. 6.6 ng/ml) increment of serum resistin levels in the GHS-
prospective design.
Model 1 Model 2
Outcome HR (95% CI) p value HR (95% CI) p value
All-cause mortality 1.33 (1.17–1.52) 2x10-5 1.28 (1.07–1.54) 0.008
Cardiovascular mortality 1.34 (1.14–1.57) 3x10-4 1.32 (1.06–1.64) 0.013
GHS, Gargano Heart Study.
Model 1: unadjusted
Model 2: adjusted for age, sex, smoking habit, BMI, HbA1c, hsCRP, anti-diabetic, anti-hypertensive andanti-dyslipidemic treatments.
doi:10.1371/journal.pone.0120419.t002
Fig 1. Search strategy for selecting studies to include in meta-analyses of resistin and all-causemortality and cardiovascular mortality (search
last run on October 2014).
doi:10.1371/journal.pone.0120419.g001
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A significant heterogeneity across studies was indeed observed (Q-test p for heterogeneity
<0.001). Sensitivity and meta-regression analyses were then performed (see Statistical Methods
section). At sensitivity analysis, HR estimates per each unitary increment of SD in resistin levels
turned out to be stable (ranging from HR = 1.13 to HR = 1.26) and quite consistent with the
HR obtained from all studies. At meta-regression analysis, among all study-level covariates
which were available from all studies (Table 4), study mean age was the only one which was sig-
nificantly associated with all-cause mortality (HR = 1.06, 95%CI:1.00–1.13, p = 0.049) (Fig. 2,
panel B), explaining 9.9% of the observed heterogeneity. The pooled HR per one SD resistin
Table 3. Main features of prospective studies included in the meta-analyses.
First author, (ref) Ethnicity Clinical set Subjects
(n)
Cause of
mortality
Mean F-U
(yrs)
Resistin (ng/ml) Deaths
(n)
Pilz et al. [11] European General population (78% w/
CAD)
1162 All-cause/CV 5.5 3.6 (2.7–5.0)* 198
Efstathiou et al. [9] European IS 211 All-cause 5.0 26.1±9.7* 101
Lubos et al. [10] European IS 1888 CV 2.6 5 (4.0–6.7)§ 70
Lee et al. [12] Korean MI 397 All-cause/CV 1.0 19.52 (14.3–25.5)
*^
28
Zhang et al. [13] American CHD 980 All-cause 6.1 8.5 (5.8–12.2)§ 274
Menzaghi et al.
[14]
European T2DM 676 All-cause 7.8 10.1±8.3§ 114
Spoto et al. [16] European ESRD 231 All-cause/CV 4.8 127.2±23.3* 165
Silva et al. [15] European T2DM 150 CV 3.0 6.1±3.5§ 35
Current study European T2DM (100% w/ CAD) 359 All-cause/CV 5.4 10.7±6.6§ 81
F-U: follow-up; CAD: coronary artery disease; IS: ischemic stroke; MI: myocardial infarction; CHD: coronary heart disease; T2DM: type 2 diabetes mellitus;
ESRD: end stage renal disease.
When not differently indicated, data are reported as mean ± standard deviation (SD).
^Approximated mean from median and approximated SD from interquartile range (IQR): under the assumption of normal distribution, then
IQR  1.35*SD.
*Data are plasma resistin concentration.
§ Data are serum resistin concentration.
doi:10.1371/journal.pone.0120419.t003
Table 4. Clinical measurements available in all prospective studies included in the meta-analyses.
First author, (ref) Age (years)* BMI (Kg/m2)* Smokers (%) Males (%) Diabetes (%) Hypertension (%)
Pilz et al. [11] 64.1±11.3^ 26.7±3.6^ 62.5 69.2 28.9 54.7
Efstathiou et al. [9] 69.1±13.8 27.5±4.7 33.0 57.3 28.4 70.1
Lubos et al. [10] 61.1±9.8 27.8±3.9 20.0 79.1 83.1 74.5
Lee et al. [12] 62.3±11.3 24.0±3.4 29.3 72 28.3 51.0
Zhang et al. [13] 66.5±10.8 28.5±5.3 19.8 81.3 26.8 70.5
Menzaghi et al. [14] 61.5±9.7 31.0±5.7 20.7 47.7 100 46.2
Spoto et al. [16] 60.0±15.0 24.5±4.4 37.2 55 15.2 36.0
Silva et al. [15] 62.7±11.0 26.3±2.7 N.A. 61.3 100 N.A.
Current study 64.5±8.1 30.2±4.8 44.5 67.4 100 85.0
When not differently indicated, data are reported as mean ± standard deviation (SD).
^Approximated mean from median and approximated SD from interquartile range (IQR): under the assumption of normal distribution, then
IQR  1.35*SD.
doi:10.1371/journal.pone.0120419.t004
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Fig 2. Forest plot for random-effects meta-analysis (panel A) and bubble plot for random-effects meta-regression with age as study-level covariate
(panel B) on all-causemortality.
doi:10.1371/journal.pone.0120419.g002
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increment, estimated from a meta-regression including study mean age was equal to 1.24 (95%
CI:1.06–1.45, p = 0.006).
CVmortality (n = 6 studies). The number of subjects from each study ranged from 150
to 1888 with a mean follow-up ranging from 1.0 to 5.5 years (Table 3).
With the only exception of our current study, none of the previous ones reported a signifi-
cant association with CV mortality [10–12, 15, 16], though 3 studies displayed a directionally
consistent association [10–12].
The pooled HR per one increment in SD of resistin concentration for CV mortality was 1.05
(95%CI: 1.01–1.10; p = 0.016), using the fixed-effects model (Fig. 3).
No significant heterogeneity across study results was observed (Q-test p for heterogene-
ity = 0.20), so that no meta-regression analysis was carried out.
Discussion
Data obtained from the GHS-prospective design confirm our previous observation that serum
resistin is a predictor of all-cause mortality [14] and extends the role of resistin also to CV mor-
tality. In addition, the role of resistin on both all-cause and CV mortality is further confirmed
by our meta-analyses carried out in all eligible published studies, most of which described, in
fact, some association [9, 11, 12, 14]. Although these positive results have to be taken with cau-
tion, investigating the association also with various non-fatal CVD events would help to deeper
understand the role of resistin on atherosclerosis [25].
Since heterogeneity was observed across studies for all-cause mortality, meta-regression
analysis was employed to get more reliable pooled HRs estimates. Although the observed re-
sults have to be taken with great caution because of the limited number of available studies,
Fig 3. Forest plot for random-effects meta-analysis on CVmortality.
doi:10.1371/journal.pone.0120419.g003
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heterogeneity was partly explained by study mean age (i.e. stronger association in studies with
older subjects).
Though our meta-regression allows speculate that age acts as a modulator of the resistin ef-
fect on all-cause mortality, only studies with individual patient data may say a last word about
this hypothesis. Unfortunately, no studies addressing this specific issue are available.
Finally, we observed a potential risk for publication bias; however, given the small number
of studies (fewer than ten) and the presence of between-study heterogeneity, we believed un-
necessary to address it in accordance with previous recommendations [23, 24].
We have to recognize some study limitations, as follows. Our meta-analyses have been con-
ducted in high-risk patients (mostly diabetic and/or with CV disease or with end stage renal
disease); so, it is unknown whether our finding applies also to “healthy” individuals with low
risk profile. In addition, most studies included in the meta-analyses were carried out in patients
from European Countries, thus making impossible to generalize our findings to population of
different ancestry and/or environmental background.
In conclusion, our results provide evidence for an association between higher circulating
resistin levels and increased mortality risk. Further studied are needed to verify whether or not
including resistin in risk engines which are already validated [26–28] improves our ability to
predict the risk of mortality, especially in high-risk individuals.
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